Nerdwallet Inc vs Novo Nordisk A/S — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $625.17M), while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 332.5× Nerdwallet Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | NVO | |
|---|---|---|
Market Cap | $625.17M | $207.85B |
Sector | Financials | Health |
52-Week High | $15.93 | $63.98 |
52-Week Low | $7.58 | $35.29 |
Enterprise Value | $539.47M | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →